-
02:23:26 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

TNXP Stock News

08/04/20 9:00 AM
Nasdaq : TNXP
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced that it has regained compliance with the minimum bid price requirement for continued listing on the NASDAQ Global Market. The Company received a letter from The NASDAQ Stock Market LLC on August 3, 2020 stating that because its shares had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company’s stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Global Market, as set forth in NASDAQ Listing Rule 5450(a)(1), and the matter is now
RHEA-AI
neutral
07/27/20 7:00 AM
Nasdaq : TNXP
clinical trial
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Virtual Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) will be presented in a poster at the American Academy of Neurology’s first-ever Sports Concussion Conference. The research was sponsored by Trigemina, Inc. and in June Tonix acquired the assets of Trigemina including certain rights to the data described on the poster.  Dr. Shashidhar Kori was formerly chief medical officer of Trigemina.  Dr. David Yeomans and Dr. Michael Klukinov are on the faculty of Stanford University.  Dr. Kori and Dr. Yeomans are currently consultants to Tonix. The virtual meeting is being held July 31 and August 1, 2020.
RHEA-AI
neutral
07/21/20 4:45 PM
Nasdaq : TNXP
Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it is rescheduling the date of the Company’s Special Meeting of Stockholders (the “Special Meeting”) previously scheduled for Friday, June 26, 2020, to Friday, August 28, 2020, at 11:00 a.m., Eastern Time. In connection with the change of the Special Meeting date, the record date for determining stockholders entitled to attend and vote at the Special Meeting has been changed to the close of business on July 15, 2020.
RHEA-AI
neutral
07/13/20 1:11 PM
Nasdaq : TNXP
Tonix Pharmaceuticals Holding Corp. Prices $10,500,000 Common Stock Offering
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 20,940,000 shares of common stock, par value $0.001 per share at an offering price of $0.50 per share, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $10.5 million before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about July 15, 2020, subject to the satisfaction of customary closing conditions.
RHEA-AI
neutral